Neuberger Berman Group LLC Boosts Holdings in Bio-Rad Laboratories, Inc. (BIO)

Sunday, 14 Jan, 2018

The institutional investor held 5,100 shares of the capital goods company at the end of 2017Q3, valued at $1.13M, up from 500 at the end of the previous reported quarter. The hedge fund run by Robert Jaffe held 49,276 shares of the restaurants company at the end of 2017Q3, valued at $2.65M, down from 61,408 at the end of the previous reported quarter. Depomed Inc now has $524.90M valuation. The stock increased 0.15% or $0.28 during the last trading session, reaching $184.18. About 75,335 shares traded. DHI Group, Inc. (NYSE:DHX) has declined 58.64% since January 11, 2017 and is downtrending. It has underperformed by 24.16% the S&P500. The stock of Bio-Rad Laboratories, Inc. Tygh Capital Mgmt Incorporated stated it has 1.24% of its portfolio in Bio-Rad Laboratories, Inc. Schwab Charles Investment Management Inc. now owns 115,218 shares of the medical research company's stock valued at $26,075,000 after buying an additional 2,070 shares in the last quarter. The company has a market cap of $7,476.76, a P/E ratio of 314.39, a price-to-earnings-growth ratio of 2.03 and a beta of 0.97. Insiders have sold a total of 9,126 shares of company stock valued at $2,309,426 in the last three months. 176,339 shares of the stock were exchanged, compared to its average volume of 182,267. Raymond James Financial Services Advisors Inc. increased its stake in Bio-Rad Laboratories by 1.2% in the 2nd quarter. It has outperformed by 37.08% the S&P500. Therefore 100% are positive. Bio-Rad Laboratories had a return on equity of 3.44% and a net margin of 1.15%. Jefferies maintained the shares of BIO in report on Thursday, June 8 with "Buy" rating. Bio-Rad Laboratories now has an average rating of "Buy" and an average price target of $277.75. Fil Ltd bought 30,559 shares as the company's stock rose 13.43% with the market.

Bio-Rad Laboratories announced that its board has authorized a stock repurchase plan on Tuesday, November 28th that authorizes the company to repurchase $250.00 million in shares. Finally, Wells Fargo & Co reaffirmed an "outperform" rating and set a $290.00 target price (up from $250.00) on shares of Bio-Rad Laboratories in a research report on Wednesday, November 29th. (NYSE:BIO) rating on Wednesday, September 7. Keefe Bruyette & Woods has "Buy" rating and $28.0 target. The stock has "Buy" rating by Jefferies on Thursday, July 13.

Since January 1, 0001, it had 0 buys, and 3 selling transactions for $1.67 million activity. Bio-Rad Laboratories has a 52 week low of $123.07 and a 52 week high of $194.20. (NYSE:BIO) on Friday, August 11. (NYSE:BIO) on Wednesday, September 13. Millennium Ltd Limited Liability Company has 0.03% invested in Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. (NYSE:BIO) soared 4.66% year-to-date.

BIO has been the subject of several analyst reports. They expect $0.57 EPS, up 9.62% or $0.05 from last year's $0.52 per share. AMGN's profit will be $2.19B for 15.28 P/E if the $3.02 EPS becomes a reality.

Tirschwell & Loewy Inc, which manages about $679.14M and $661.33M US Long portfolio, upped its stake in Henry Schein Inc. TSINGOS CHRISTINE A sold $1.24 million worth of stock or 4,980 shares. B Riley Finl Inc was raised too. Strong Sell. Investors might also notice that two months ago the Buy recommendations (1) outnumbered Sell recommendations (0). Its down 0.46, from 1.24 in 2017Q2.

Among 6 analysts covering AllianceBernstein Holding (NYSE:AB), 3 have Buy rating, 0 Sell and 3 Hold. 37 funds opened positions while 64 raised stakes. Breton Hill Limited holds 0.04% or 1,045 shares.

Canada Pension Plan Investment Board increased its stake in Bio Rad Labs Inc Cl A (BIO) by 920% based on its latest 2017Q3 regulatory filing with the SEC. State Teachers Retirement has invested 0.01% in Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, November 2nd. Also, the Hold rating count is 0, as of 10 Jan 2018. Credit Suisse AG boosted its stake in shares of Bio-Rad Laboratories by 37.7% in the third quarter. It also reduced its holding in Cemex Sab De Cv (NYSE:CX) by 159,291 shares in the quarter, leaving it with 337,549 shares, and cut its stake in Hubbell Inc. Peak6 Invests LP stated it has 449 shares or 0% of all its holdings. Meeder Asset Mngmt has 618 shares for 0.01% of their portfolio. The consensus earnings estimates for the company have stabilized at US$1.07 per share.

Schwerin Boyle Capital Management Inc decreased its stake in Cummins Inc (CMI) by 28.06% based on its latest 2017Q3 regulatory filing with the SEC. 86,228 were reported by Franklin Resources. Following the sale, the executive vice president now owns 2,492 shares of the company's stock, valued at approximately $643,907.88. Salem Management holds 0.12% or 1,200 shares in its portfolio.

Since September 7, 2017, it had 0 buys, and 2 sales for $4.70 million activity. State of Wisconsin Investment Board now owns 4,187 shares of the medical research company's stock valued at $948,000 after buying an additional 40 shares during the period. Out of 2 Wall Street analysts rating Bio-Rad Labs, 1 give it "Buy", 0 "Sell" rating, while 1 recommend "Hold". Therefore 46% are positive. Dice Holdings had 6 analyst reports since August 31, 2015 according to SRatingsIntel. Morgan Stanley reinitiated Depomed, Inc. The firm has "Equal-Weight" rating given on Friday, October 13 by Barclays Capital. The firm has "Hold" rating given on Tuesday, November 8 by Cantor Fitzgerald. (NYSE:CMI) on Monday, April 11 to "Neutral" rating. The firm has "Buy" rating given on Wednesday, November 11 by TH Capital. The stock of Cummins Inc. (NASDAQ:AMGN) earned "Market Perform" rating by Bernstein on Wednesday, June 29. The firm has "Buy" rating by Jefferies given on Wednesday, April 12.